Needle-Free Skin Patch Delivery of a Vaccine for a Potentially Pandemic Influenza Virus Provides Protection against Lethal Challenge in Mice
- 1 July 2007
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (7) , 926-928
- https://doi.org/10.1128/cvi.00450-06
Abstract
In the event of another influenza virus pandemic, strategies for effective mass vaccination will urgently be needed. We used a novel transdermal patch delivery technology, known as the PassPort system, to vaccinate mice with recombinant H5 hemagglutinin with or without immunomodulators. This needle-free form of vaccine delivery induced robust serum antibody responses that were augmented by different immunomodulators that stimulated the innate immune system and protected mice against lethal challenge with a highly pathogenic avian H5N1 influenza virus.Keywords
This publication has 25 references indexed in Scilit:
- Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialThe Lancet, 2006
- Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccineVirus Research, 2004
- Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccinesGene Therapy, 2003
- Safety and Immunogenicity of a Prototype EnterotoxigenicEscherichia coliVaccine Administered TranscutaneouslyInfection and Immunity, 2002
- Macroflux® Microprojection Array Patch Technology: A New and Efficient Approach for Intracutaneous ImmunizationPharmaceutical Research, 2002
- Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine).2002
- Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and childrenVaccine, 2001
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001
- Transcutaneous Immunization: An Emerging Route of Immunization and Potent Immunostimulation StrategyCritical Reviews in Therapeutic Drug Carrier Systems, 2001
- Transcutaneous immunization: A human vaccine delivery strategy using a patchNature Medicine, 2000